Owkin Shares Federated Learning Tool for Secure RNA-Seq Analysis
Owkin has released FedPyDESeq2, a federated learning tool for differential expression analysis (DEA) in bulk RNA sequencing (RNA-seq). Designed to …
All Posts
Citryll Secures €85M to Advance Monoclonal Antibody Targeting NETs in Inflammatory Diseases
Citryll, a biotechnology company focused on developing monoclonal antibody therapies to address immune-mediated inflammatory diseases, has completed an €85 million …
The AI-driven Development Journey of ISM5411, a Potential Breakthrough Treatment for Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD), a chronic and debilitating autoimmune disorder that includes ulcerative colitis and Crohn’s disease, impacts millions of …
Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio with $75 Million Financing
Chroma Medicine and Nvelop Therapeutics have announced their merger to form nChroma Bio, a new biotechnology company focused on advancing …
DASA Launches Microbial Forensics Competition to Enhance UK Biosecurity
The Defence and Security Accelerator (DASA), in partnership with the Defence Science and Technology Laboratory (Dstl), has launched a new …
Tasca Therapeutics Launches with $52 Million to Advance Precision Oncology
Tasca Therapeutics, a biotechnology company focused on small molecule inhibitors for oncology, has raised $52 million in Series A financing. …
Dot Compliance Expands AI Capabilities to Transform Quality and Compliance in Life Sciences
Dot Compliance, a provider of AI-powered compliance and electronic quality management system (eQMS) solutions, has introduced the third generation of …
Cradle Achieves 8x Improved EGFR Binding Over Merck’s Cetuximab in Protein Design Challenge
Cradle’s platform has achieved first place in Adaptyv Bio's protein design competition by producing a novel EGFR-binding protein with a …
The Importance of Accurate Patient Matching for AI Projects
Artificial intelligence (AI) is revolutionizing healthcare by enhancing workflows, enabling earlier diagnoses, and paving the way for personalized care. However, …
AQEMIA Reaches $100 Million in Funding, Plans Expansion and Prepares for Clinical Trials
AQEMIA, a techbio company teaching atomic scale physics to a generative AI, has announced reaching $100 million in cumulative funding. …
Recursion Reports Encouraging Interim Phase 1 Data a Selective CDK7 Inhibitor
Recursion (Nasdaq: RXRX) announced interim findings from the ongoing Phase 1/2 ELUCIDATE trial evaluating REC-617, a precision-designed, oral CDK7 inhibitor …
BioAge Labs Halts STRIDES Phase 2 Trial of Azelaprag-Tirzepatide Combo
BioAge Labs, which recently raised upwards of $198 million through an upsized IPO in September 2024 to fund its clinical …